Skip to main content
  • PCSK9 Inhibition May Reduce Inflammation, Mortality in Patients with Severe COVID-19

    Patients with intense COVID-19 inflammation while infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have better survival rates with PCSK9 inhibition than with placebo treatment, a new study shows.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details